Healthy Participants
Conditions
Interventions
Group 1: Single consumption:
In study arm 1, healthy participants aged 18-65 years are administered (i.e. inhaled via a vaporizer) a study intervention (1) CBD >15%, THC 0.7-1%
2) CBD >15%, THC = 0.3%
3) CBD and THC = 0.2%). Before the intervention urine and blood samples are collected. Blood might be sent for analysis of polymorphisms of metabolizing enzymes such as cytochrome P450 family and UDP-
Sponsors
Institut für Rechtsmedizin der Universität Basel
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 18-65 years, driving license category B, sufficient knowledge of German language, experience with nicotine and/or cannabis products.
Exclusion criteria
Exclusion criteria: Psychiatric or physical disease (including addictive disorders), long-term medication, drug or alcohol abuse, insufficient knowledge of German language, no current driving license, pregnancy, breastfeeding or planned pregnancy in women, no experience with nicotine or cannabis products, limited availability, non-compliance regarding abstaining from alcohol, controlled substances, cannabis products (incl. CBD cannabis other than study intervention), non-compliance regarding abstaining from driving on study days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood and urine concentrations of CBD and THC after CBD-cannabis consumption. | — |
Secondary
| Measure | Time frame |
|---|---|
| Driving ability after CBD-cannabis consumption. | — |
Countries
Switzerland
Contacts
Public ContactLaura Egloff
Institut für Rechtsmedizin der Universität Basel
Outcome results
None listed